alfuzosin hydrochloride / Generic mfg. - LARVOL DELTA

COPE Trial: comparison of yoga therapy versus medical therapy in men with chronic pelvic pain syndrome-a pilot randomised crossover trial. (PubMed, Int Urol Nephrol) - "YT was not inferior to alfuzosin plus amitriptyline (MT) for improving symptoms in men with CPPS and had fewer side effects. Yoga could be used as an add-on or maintenance therapy while MT could be more preferable in men with predominant urinary symptoms."

Journal • Gynecology • Musculoskeletal Pain • Pain • Urology

Taste-Masked Orodispersible Tablets of Alfuzosin hydrochloride: Response Surface Methodology (RSM) Based Approach for Enhanced Patient Compliance in BPH Management. (PubMed, Pharm Dev Technol) - "The optimized formulation showed rapid disintegration (10.72 sec), low friability (0.261%), adequate hardness (5.28 kg/cm2), and 99.21% drug release within initial 15 min. Taste evaluation using an Alpha MOS electronic tongue confirmed effective masking of the drug's inherent bitterness and the study demonstrated the potential of optimized ODTs as a patient-friendly dosage form for effective BPH management."

Compliance • Journal • Benign Prostatic Hyperplasia • Gastrointestinal Disorder • Geriatric Disorders

PH3 in youngers: a very rare disease with different presentations (ERA 2026) - "Treatment included potassium citrate (1 g/kg/day), mild hydration, and alfuzosin, resulting in spontaneous stone passage with renal colic...Why this case is exeptional The first case is the earliest reported PH3 onset; the second shows typical onset that could lead to extensive kidney stones if not diagnosed early. Early specialist review of ultrasounds is recommended to avoid delayed or complex care."

Nephrology • Rare Diseases • Renal Calculi • Renal Disease • Urolithiasis

Comparative Safety Profiles of a1-Adrenergic Blockers in Men with LUTS: Insights from a FAERS Disproportionality Study (AUA 2026) - "After deduplication per FDA guidance, only male cases listing alfuzosin, doxazosin, tamsulosin, terazosin, or silodosin as the primary suspect drug were included. This large-scale FAERS analysis reveals distinct safety fingerprints within the α-blocker class. Highly selective agents (tamsulosin, silodosin) were characterised by strong ejaculatory and ocular signals, whereas less selective agents (terazosin, doxazosin) displayed prominent vasodilatory patterns. These findings complement clinical evidence and support individualised α-blocker selection based on patient comorbidities and treatment priorities."

Clinical • Hypotension • Ophthalmology

Comparison of the efficacy of alfuzosin and mirabegron on symptoms associated with Double-J stent placement after retrograde intrarenal surgery. (PubMed, Urol Ann) - "The relatively small sample size and single-center design represent important limitations of this study. Further large-scale, multicenter studies are warranted to clarify the potential role of these agents in the management of DJ stent-related symptoms."

Journal • Nephrology • Overactive Bladder • Pain • Renal Calculi

Case of Importance of Pituitary Function Monitoring After Gamma Radiotherapy (AACE 2026) - "The initiation of desmopressin improved polyuria and headaches, consistent with central DI. However, the concomitant use of alfuzosin, may have worsened his predisposition to orthostatic hypotension, already"

Clinical • Benign Prostatic Hyperplasia • CNS Disorders • Endocrine Disorders • Epilepsy • Hypotension • Pituitary Gland Carcinoma

Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS). (PubMed, Aging Male) - "Reports of adverse events (AEs) in male BPH patients receiving AUA guideline-recommended drugs including α-1 blockers (tamsulosin, silodosin, doxazosin, and alfuzosin), 5ARIs (finasteride and dutasteride), and tadalafil were extracted. Sixteen significant AEs were detected, including pollakiuria, gynecomastia, breast pain and so on, with distinct reporting patterns across drug classes. This large-scale pharmacovigilance analysis identified distinct post-marketing safety signals among guideline-recommended pharmacotherapies for BPH, confirming known risks and suggesting potential novel adverse-event signals warranting further investigation."

Adverse events • Journal • Real-world evidence • Retrospective data • Benign Prostatic Hyperplasia • Pain

Anterior segment, static and dynamic pupillography changes in patients using different types of alpha-1 blockers. (PubMed, Doc Ophthalmol) - "The alpha-1 blockers included in this study were those most commonly used in clinical practice. Our results showed that, as aspected, alpha-1 blockers do not change the anterior segment. Three of the groups showed no abnormal pupil behaviour, but the diameter was significantly smaller in the doxazosin group."

Journal • Benign Prostatic Hyperplasia

Do Alpha-Blockers and 5-Alpha Reductase Inhibitors Increase Dementia Risk? A Network Meta-analysis. (PubMed, Int Neurourol J) - "This study found no significant association between the use of alpha-blockers or 5ARIs and increased dementia risk. These findings may assist clinicians in making more informed prescribing decisions, particularly for older male patients with BPH. Further large-scale research with extended follow-up periods is needed to strengthen the evidence across all BPH medications."

Journal • Retrospective data • Alzheimer's Disease • Benign Prostatic Hyperplasia • CNS Disorders • Dementia

Efficacy of alpha-blockers in medical expulsive therapy for ureteral stones: A systematic review and meta-analysis of randomized controlled trials between 2010 and 2025. (PubMed, Arab J Urol) - "Network meta-analysis revealed efficacy ranking favoring at first terazosin, followed by doxazosin then, silodosin then, tamsulosin then, alfuzosin and last the least effective was naftopidil. While tamsulosin remains the most studied agent, our network meta-analysis suggests terazosin and doxazosin may offer superior efficacy. The favorable risk-benefit profile supports routine use of alpha-blockers for appropriately selected patients with ureteral stones."

Journal • Retrospective data • Review • Pain • Renal Calculi • Urolithiasis

Differential Risks of Dementia, Depression, and Injury Among Common α-Blockers, with Tamsulosin as the Reference Drug: A Real-World Cohort Study in Men with Lower Urinary Tract Symptoms. (PubMed, J Clin Med) - "Patients were grouped by α-blocker type-tamsulosin, doxazosin, terazosin, alfuzosin, silodosin, or prazosin-and matched 1:1 using propensity scores to adjust for demographic, clinical, and psychosocial variables. Given its favorable profile, alfuzosin may be the preferred agent in patients at elevated risk of cognitive or psychiatric disorders. These findings highlight the need for individualized α-blocker selection and long-term pharmacovigilance in BPH management."

Journal • Real-world evidence • Alzheimer's Disease • Benign Prostatic Hyperplasia • CNS Disorders • Dementia • Depression • Mental Retardation • Oncology • Psychiatry

Non-Catalytic Inhibitors of the p38/MK2 Interface: Repurposing Approved Drugs to Target Neuroinflammation in Alzheimer's Disease. (PubMed, J Med Chem) - "Virtual screening of FDA-approved drugs prioritized nilotinib, a BCR-ABL inhibitor, as a putative PPI disruptor...Guided by these findings, we developed a lysate-based TR-FRET ultrahigh-throughput assay that identified additional inhibitors, including α1-adrenergic antagonists doxazosin, terazosin, and alfuzosin. These compounds suppressed cytokine induction via docking groove blockade. Together, these results establish a non-ATP-competitive approach for selectively targeting the p38/MK2 complex and highlight the translational potential of drug repurposing to modulate neuroinflammation in Alzheimer's disease."

Journal • Alzheimer's Disease • CNS Disorders • Inflammation • ABL1 • BCR

Silodosin in treating men With BPH-associated lower urinary tract Symptoms: A systematic review and network meta-analysis. (PubMed, Int J Surg) - "Silodosin is highly effective for BPH-LUTS, particularly for voiding symptoms, but carries a elevated risk of ejaculatory dysfunction. Combination with tadalafil may enhance urinary flow. Clinicians should weigh efficacy against adverse events; further trials are needed to confirm long-term benefits."

Journal • Retrospective data • Benign Prostatic Hyperplasia

Alfuzosin-Induced Autoimmune Hepatitis: A Rare Case Report. (PubMed, Turk J Gastroenterol) - No abstract available

Journal • Autoimmune Hepatitis • Immunology • Inflammation

Development and Characterization of Sensitive, Eco-Friendly, and Selective Microwave-Aided Fluorodensitometric Probe for Estimation of Alfuzosin Using Comprehensive Approach of Multicolored Analytical Chemistry and Design of Experiments. (PubMed, Luminescence) - "The method was successfully applied to pharmaceutical formulations and different plasma samples. The proposed method offers a sensitive, selective, and environmentally friendly approach for AFZ estimation at picoscale levels, adhering to white analytical chemistry principles and the QbD approach."

Journal

Management of acute urinary retention in men with benign prostatic hyperplasia: Literature review and guidelines from the French Urological Association Male LUTS Panel (CTMH). (PubMed, Fr J Urol) - "These CTMH guidelines provide evidence-based recommendations for AUR management, emphasizing alpha-blocker therapy before trial without catheter and considering patient-specific factors when selecting drainage methods. Further research is needed to optimize surgical timing and technique selection."

Clinical guideline • Journal • Review • Anesthesia • Benign Prostatic Hyperplasia

The Discovery of α-Adrenoceptor Antagonists as a Potential New Treatment Option for Uveal Melanoma. (PubMed, Biomolecules) - "Drug screening with UM spheroids revealed that prazosin and doxazosin dose-dependently reduced viability, whereas terazosin, alfuzosin, silodosin, tamsulosin, and phenoxybenzamine were found to be inefficient. This suggests a tumor-preventive effect through the blockade of α1A-AR. The present study highlights the responses of UM spheroids to α-AR antagonists and demonstrates that prazosin, doxazosin, or RS17053 may be a treatment option for preventing UM tumor recurrence or metastasis."

Journal • Eye Cancer • Hepatocellular Cancer • Melanoma • Ocular Melanoma • Oncology • Solid Tumor • Uveal Melanoma • AR

Comparison of the First Dose and Efficacy of Alfuzosin, Tamsulosin and Silodosin in the Treatment of Benign Prostatic Hyperplasia. (PubMed, Arch Esp Urol) - "Silodosin provided the most rapid symptomatic improvement following initial administration, likely due to its high α1A-receptor selectivity. However, by the third month, all three agents showed similar clinical efficacy, supporting their use as viable treatment options tailored to patient-specific needs."

Clinical • Journal • Retrospective data • Benign Prostatic Hyperplasia

Efficacy of Hexanic Serenoa repens Extract Combined With Alfuzosin Versus Alfuzosin Alone in Men With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Multicenter Randomized Study. (PubMed, Prostate) - "The combination of HESr and alfuzosin was significantly more effective than alfuzosin monotherapy in relieving LUTS, with greater benefits from Month 3 onward. Qmax and nocturia also showed greater, although mild, improvements with combination therapy. Sexual function outcomes were comparable between groups. High adherence and real-world applicability support the clinical value of this combination in managing BPH-related LUTS."

Journal • Benign Prostatic Hyperplasia • Inflammation

Novel Compounds in Targeting the α1-adrenoceptor for Antihypertensive Therapy. (PubMed, Cardiovasc Hematol Agents Med Chem) - "Terazosin, doxazosin, tamsulosin, and alfuzosin are examples of α1-adrenoceptor antagonists that have antihypertensive properties; however, they are linked to considerable side effects, including headaches, dizziness, reproductive problems, and postural hypotension. In the last several years, a number of novel α1-adrenergic antagonists have been synthesised by modifications of various pharmacophores such as Isochroman-4-one, Quinazolines, Piperazine, and Quinazoline-triazole, etc. The present review highlights recently synthesized α1-adrenoceptor antagonists for the management of hypertension, and emphasizes their structure-activity relationship and subtype selectivity."

Journal • Cardiovascular • Hypertension • Hypotension • Myocardial Infarction • Pain

Electromotive Drug Administration in the Porcine Ureter: First In Vivo Application for Ureteral Dilation. (PubMed, J Endourol) - "Neither aminophylline nor isoproterenol with EMDA resulted in a significant increase in ureteral size compared with their respective NS controls (aminophylline vs NS, 0.3 Fr vs -0.6 Fr, p = 0.344; isoproterenol vs NS, 0.1 Fr vs -0.4 Fr, p = 0.125). In this first report, EMDA-mediated in vivo delivery of alfuzosin into the porcine ureter acutely increased ureteral distensibility."

Journal • Preclinical

Prophylactic alpha-blockers for prevention of post-operative urinary retention after total mesorectal excision for cancer: A prospective multicenter study from the GRECCAR group (ESCP 2025) - "LOS was significantly shorter with Alfuzosin compared to both standard care(6 days [2-60] vs. 10 days [4-72],p<0.001) and Silodosin(8 days [5–40],p<0.001). Conclusion Prophylactic Alfuzosin significantly reduces post-operative urinary retention and re-catheterization rate after TME with a shorter LOS.This Alfuzosin protocol should be implemented in early rehabilitation programs in order to improve postoperative outcomes after rectal surgery."

Clinical • Benign Prostatic Hyperplasia • Colorectal Cancer • Oncology • Prostate Cancer • Rectal Cancer • Solid Tumor

Prostatitis: A Review. (PubMed, JAMA) - "First-line therapy for chronic bacterial prostatitis is a minimum 4-week course of levofloxacin or ciprofloxacin...First-line oral therapy for CP/CPPS with urinary symptoms is α-blockers (eg, tamsulosin, alfuzosin; ΔNIH-CPSI score difference vs placebo = -10.8 to -4.8). Other oral therapies are associated with modest changes in NIH-CPSI score compared with placebo, including anti-inflammatory drugs (eg, ibuprofen; ΔNIH-CPSI score difference = -2.5 to -1.7), pregabalin (ΔNIH-CPSI score difference = -2.4), and pollen extract (ΔNIH-CPSI score difference = -2.49). Prostatitis includes acute bacterial prostatitis, chronic bacterial prostatitis, and CP/CPPS, each of which is diagnosed and treated differently. First-line treatments are broad-spectrum antibiotics for acute bacterial prostatitis (such as piperacillin-tazobactam, ceftriaxone, or ciprofloxacin), at least 4 weeks of fluoroquinolones for chronic bacterial prostatitis, and α-blockers for CP/CPPS with urinary symptoms."

Journal • Gynecology • Infectious Disease • Musculoskeletal Pain • Nephrology • Oncology • Pain

Alfuzosin and Mirabegron for Double-J Stent Symptoms (clinicaltrials.gov) - P=N/A | N=100 | Completed | Sponsor: University of Gaziantep

New trial

An eco-friendly HPLC method for the sustainable analysis of the newly approved combinations of Alfuzosin and Tamsulosin, with Tadalafil in organic-solvent-free mixed-micellar systems. (PubMed, Analyst) - "Greenness of the method was assessed using the Analytical GREEnness metric approach (AGREE), and the blueness was assessed using blue applicability grade index (BAGI), with scores of 0.76 and 82.5, respectively. These scores underline the superiority of the proposed procedure over previously reported methods."

Journal • Benign Prostatic Hyperplasia • Urology